CHI3L1 and Parkinson disease: In summary, the herein presented results describing significantly increased levels of YKL-40 in AD patients compared to non-demented controls and patients with PD or DLB, confirm and extend previous studies suggesting CSF YKL-40 as a clinical biomarker candidate for the differential diagnosis of AD dementia.